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A B S T R A C T
Clinical cytology is a diagnostic branch of medicine, best known by the Papa test in gynaecology. But, cytology can be
applied in almost all fields of clinical medicine. Its advantages – high accuracy, simplicity, with little or no aggressive-
ness and low cost – are not used as widely as they could be. Medical practice, as well as medical research, and also medi-
cal education, are nowadays often directed at profitable use and not at the real benefit of the patient. Primary practitio-
ners do not have enough chance to get acquainted with clinical cytology as a whole although they need true information,
based on the cost-effectiveness and patient-benefit. A panel discussion on this subject was organised at the 4th Croatian
Congress of Clinical Cytology, in Split, October 11–14, 2009 by the Croatian Society for Clinical Cytology-Croatian Medi-
cal Asoctiation, to inform primary practitioners about the possibilities of cytodiagnostics in the health care of children
and adults. Indications for cytodiagnostics in infectious diseases (T. Jeren and A. Vince), haematology (I. Kardum-
-Skelin), pulmonology (S. Smojver-Je`ek), thyroid diseases (A. Kne`evi}-Obad), breast diseases (I. Kardum-Skelin), gas-
troenterology and urology (G. Kai}) were discussed, as well as technical procedures and the interpretation of the cytologi-
cal findings. Moderator (@. Znidar~i}) opened the panel with presentation about the role of clinical cytology, particularly
in the primary health care. The discussion finally pointed at the necessity of better communication between primary prac-
titioners and cytologists. This review article presents contents of the panel discussion.
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Introduction
The actual problem in modern medicine is its frag-
mentation into many small parts without an adequate
connection among them. The target of interest now is
not the patient as a whole person with some health prob-
lems. The actual medicine is concentrated on the distinct
parts of this person, his organ, or just a part of an organ.
Doctors are overloaded with everyday developments of
medical science and are therefore specialized in very nar-
row branches. In such circumstances complete survey of
the whole medical knowledge is inevitable lost. This situ-
ation has been profitably used at the expense of both pa-
tients and doctors. In diagnostics, efforts are constantly
directed at new technologies, with expensive equipment
and at the laboratory tests with numerically expressed
results. The doctors increasingly turn into technicians1.
»Evidence based medicine« is the expression often used
to justify this transformation. The medical science is also
directed at providing new technologies and medicaments
used for the profit and not for the general improvement
of health. Modern medicine is becoming more and more
expensive and this is the world-wide problem. The acces-
sibility of medical procedures is inversely proportional to
the quantity of these procedures. That results in reduced
effects of the medical treatment, which is an absurd. The
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primary practitioners are the first ones handicapped by
this problem. Medical education is not concerned about
the economics in the health care and the physicians are
exposed to advertising of various diagnostic technologies,
laboratory procedures and chemical substances. It is ob-
vious that the main goal of advertising is the profit and
not the patients benefit, although great efforts are made
to demonstrate this benefit »scientifically«. There al-
ready are a great number of articles in respectable medi-
cal journals, or even books, where the truth about vari-
ous new technologies and medicaments is exposed2. But,
in the health care management the physicians should
have true information, based on the cost- and patient-
-benefit. Thus, it is necessarry for primary care practitio-
ners to be informed about possibilities of diagnostic cy-
tology, especially because of insufficient information they
get during medical studies. The indications for cytodiag-
nostics, the way of specimen collection for cytoanalysis
and the interpretation of cytological findings are there-
fore stressed in our discussion. We hope, nevertheless,
that in the near future the situation in medicine will
change and that the cost-effectiveness and patients bene-
fit, rather than profitability, will be the primary concern
in the health care management. We are all invited to do
our best to promote this change.
Cytology as a Clinical Diagnostic Branch
The discovery of cells, as the consequence of the mi-
croscope construction in the 17th century, marked the be-
ginning of cytological investigations. Technical improve-
ments of the microscope gave successively more knowl-
edge about the structure and the function of the cells and
of their morphological changes in various functional and
pathological conditions. The statement of Rudolf Vir-
chow, that each pathological process begins in the cell,
has led the scientists to investigate the cells and their
morphological changes. Thus the diagnostic role of the
cytologic analysis was established. But, nevertheless, a
rather long period was necessary for the development of
clinical cytology as a medical diagnostic branch. It star-
ted with Papanicolaou in the first decades of the 20th cen-
tury, in gynaecology, and then it was successively introdu-
ced into other medical fields as a morphologic diagnos-
tics, with many advantages. In short, cytology has a high
diagnostic accuracy, the methods of the material collec-
tion are simple, with little or no aggressiveness, and at a
low cost. The diagnosis can often be given in a very short
time, even intraoperatively. Cytology can save time and
money, and avoid the hospitalization – the advantages
needed in the actual medicine, but not sufficiently
used3,4. Perhaps the main reason for neglecting diagnos-
tic cytology in modern medical practice and education, is
lack of financial profitability of this diagnostic branch.
Our medical students are informed about gynaeco-
logical part of cytology during the gynaecological course,
and the general cytology is a short optional subject in
some medical schools in Croatia. The main factors neces-
sary for appropriate use of cytology are a sufficient num-
ber of adequately educated and trained cytologists and
cytotechnicians and a properly organized team-work with
the hospital doctors and other personnel as well as with
the primary practitioners, who should be also adequately
educated. The specialization in cytology exists in Croatia
for 35 years now and it was established to qualify doctors
in the complete cytodiagnostics. Cytotechnicians are ed-
ucated to do the technical part of cytology and to screen
slides and separate normal slides from the pathological
ones, which should be analysed by the cytologists. Ac-
cording to the way of obtaining the material for cyto-
analysis, two main parts of cytology are distinguished:
exfoliative and aspiration cytology. When the cells are ob-
tained from a surface where they are scaled, as in the
exfoliative cytology, the specimen collection is simple and
it can be used for the screening of asymptomatic popula-
tion to discover premalignant changes or early stages of
malignant ones. A great number of normal slides, with-
out pathological changes, are obtained in such a way, and
an insufficient number of cytotechnicians is often the
reason for the prolonged waiting for the cytological re-
ports in gynaecology. In the aspiration cytology, where
the material is obtained by fine-needle aspiration, done
usually under radiological guidance (ultrasound, CT, x-
-ray), the cytotechnicians can separate slides with unsati-
sfactory material (e.g. blood only) but the cytologists
should always analyse smears with satisfactory material.
Current cytological service in Croatia is organized in 46
cytological units (in 23 towns), with 101 specialist of clin-
ical cytology, 20 residents in clinical cytology, 141 cyto-
tehnicians and 45 medical technicians without cytote-
chnological training5. The cytologists: cytotechicians ratio
is unsatisfactory, but there is another problem with the
total number of the cytological personnel. To make the
best of cytology with all its advantages, the number of cy-
tologists, as well as cytotechnicians, should correspond to
the number of specialists in other medical branches who
need cytology in their diagnostic work. Cytology can be
used in the early diagnosis or even prevention of malig-
nancy, but also in the diagnosis of various non-malignant
diseases, as well as in the follow-up of the treatment. The
number of cytological staff should be considerably greater
and the cytologists: cytotechnicians ratio should be at
least 1:2.
The aim of this round table discussion was to inform
primary practitioners about cytology, especially in the
medical fields where it is widely used. The participants in
the discussion should provide information about the in-
dications for cytodiagnostics in these fields, as well as in-
formation about the collection of material and about the
interpretation of the cytological reports. Better commu-
nication between the cytologists and the primary practi-
tioners is necessary to improve the rule of cytodiagno-
stics in the health care6.
Cytology in Infectology
Infectious diseases, most often with inflammatory
pathogenesis, can be caused by various microorganisms:
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bacteria, fungi, viruses, parasites, or there is sometimes
a combination of inflammatory and degenerative pro-
cess, like in the prionic diseases. There are special prob-
lems in infectious diseases accompanying immunological
disorders7.
The role of cytology in the diagnosis of infectious dis-
eases is very important. Many infectious diseases, with
common infectious symptoms like fever, chills, headache,
prostration, have specific, diagnostically significant sym-
ptoms which help in their differentiation. So there are
skin signs: rash, maculas, papulas, vesiculas or other
manifestations. Mucous lesions are also often present:
vesiculas, infiltrates (serous or purulent) or other chan-
ges.
Very often there are enlarged lymph nodes in one or
several regions, sometimes adherent to each other, some-
times with fistulation and skin inflammation around
them. They are usually painful. Respiratory organs are
often involved, sometimes with mild serous inflamma-
tion, but sometimes with serious pneumonia, where ana-
lysis of sputum is important in the differential diagnosis.
Gastrointestinal infections can produce diarrhoea with
various appearance of feces. In the urogenital infections,
qualitative and quantitative changes of urine or some
other excretes (prostate, vagina) can appear.
Indications for cytological examination in differen-
tial-diagnostic procedures in the infectology are various
specific and non-specific symptoms mentioned above,
which should also be investigated by laboratory analyses
(haematological, microbiological, biochemical and oth-
ers). Cytological examinations in various infectious dis-
eases are simple, minimally invasive, and can be re-
peated when necessary. They can be performed in every
institution where persons trained in cytology (cytologist
and cytotechnician) are available. The material for cyto-
analysis is sometimes obtained by exfolliation (skin, mu-
cous membranes – smear, vesicular fluid), as in herpetic
or pemphigoid lesions8,9.
Fine needle aspiration (FNA) of enlarged lymph no-
des is a very frequent procedure for obtaining material
for cytodiagnosis in infectology. Lymphatic tissue is re-
acting in almost all infectious diseases, and lymphade-
nopathy can be localized or generalized. Such reactions
are present even without clinical symptoms. Reactive
changes of the lymphatic tissue cannot be always pal-
patory evident, but cytological and pathohistological chan-
ges are always present. The primary practitioner should
know that, in the first 30 years of life, about 80% of
lymphadenopathies are benign, but later the percentage
of malignant diseases increases (40% are benign after 50
years of age)10. In the diagnostic procedure, a thorough
anamnesis and clinical examination of the patient with
enlarged lymph nodes are followed by the FNA of lymph
node(s).
The dynamics of cytomorphological picture in infec-
tious diseases should be stressed, so that a process can
begin with lymphocytic hyperplasia and end as a gra-
nulomatous inflamation. It is also necessary to know
that some malignant processes can begin as lymphocytic
hyperplasia, follow-up of the disease is therefore recom-
mended in such cases.
Sputum cytology is important for the differentiation
of an inflammatory from a malignant process11. The ex-
pectorate and not just saliva should be obtained from the
patient. Urogenital infections can often be diagnosed by
urine examination. The patient must be informed to give
the first morning urine (but not noctural), at best in the
medical institution as it should be fresh for cellular ex-
amination. The cytological examination of the feces is
necessary especially in children with diarrhoea, to differ-
entiate the viral from the bacterial process. In adults it
can help in the diagnosis of ulcerous inflammation of the
colon as well as in the follow-up of the disease and the
therapy. Fresh samples of feces should be taken several
times.
In all inflammatory processes of the central nervous
system (CNS), cytological examination of the CSF (ob-
tained by lumbar puncture) is the first step in diagnostic
procedure. In purulent inflammatory processes, most
commonly caused by bacteria, and possibly by fungi and
some parasites, pleocytosis in CSF is detected with sev-
eral hundreds to tens of thousands of cells per cubic mil-
limeter. Cytological analysis reveals neutrophils that do-
minate from 3 to 8 days depending on the etiology,
pathogen virulence and time of initiation of adequate
therapy, after which the neutrophil curve is crossed by
the mononuclear cells (lymphocytes, monocytes and ma-
crophages) curve.
In viral inflammations, most commonly caused by
neurotropic viruses, pleocytosis is milder, with several
dozens to several hundreds of cells per cubic millimeter.
Immediately after initial neutrophilia that lasts for 4–6
hours, maximum 24 hours, mononuclear pleocytosis mai-
nly occurs with lymphocytes, monocytes, various stimu-
latory forms of these cells, immunocompetent cells and
some macrophages. In inflammatory processes that af-
fect mainly the brain (encephalitis), pleocytosis is mild
and immunocompetent cells are often found. Cytological
findings of the CSF in tumor processes are important in
the diagnostics of hematogenous metastases in the CNS,
because tumor cells are largely found in the CSF itself. In
primary CNS tumors that affect the CSF spaces (e.g.
ependymoma), tumor cells are also detected in the CSF,
and in primary tumors that are located away from the
CSF spaces, tumor cells may not be found in the CSF,
only the so called reactive pleocytosis, which is not suffi-
cient for establishing the diagnosis.
The cytological examinations and findings described
here contribute in the diagnosis of an infectious disease,
which should be etiologically proved (data from personal
lectures at the School of medicine, Zagreb University).
The communication between primary practitioners and
cytologists is a »conditio sine qua non«. It consists of the
informations about significant anamnestic, clinical and
laboratory data and a presumed working diagnosis, on
the side of primary practitioner. The cytologist, on his
side, should give the answer after a thorough cytological
analysis – compatible with presumed diagnosis, defini-
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tive diagnosis or differential diagnostic possibilities. The
communication is as yet not sufficient and it should be
improved, to get more objective diagnoses and more suc-
cess in the treatment of our patients.
Hematologic Cytology
Enlarged lymph node is a perfect model for the pa-
tient, the clinician/primary practitioner and the cytolo-
gist to see how a sample obtained by cytologic fine-needle
aspiration (FNA) can serve to differentiate a non-malig-
nant from a malignant process with certainty, which is
the main cytologist’s responsibility, by use of cytomor-
phology and adjuvant technologies12. The indications for
lymph node FNA depend on the patients age, clinical
presentation, and size, consistency and localization of en-
larged lymph nodes. Lymph node enlargement is part of
the patient’s normal immune response to various agents.
In childhood, when the body encounters various caus-
ative agents for the first time, lymph node enlargement
is an almost daily phenomenon. Unnecessary exposure of
pediatric patients to FNA procedure can be avoided by
appropriate clinical follow up. FNA is indicated in cases
where clinical picture offers no explanation for lymph
node enlargement, when lymph node enlargement per-
sists or even increases in spite of therapy administered.
In adult patients, any lymph node enlargement requires
attention and search for the causative agent (local or sys-
temic infection). Injuries or skin changes on lower ex-
tremities and genitourinary tract inflammation are the
most common causes of inguinal lymph node enlarge-
ment. By analogy, axillary lymph nodes respond with en-
largement to respective lesions of upper extremities, tho-
rax and breast. Inflammatory lesions in the head and
neck region generally lead to reactive changes in cervical
lymph nodes. In addition to reactive and inflammatory
changes in acute inflammation, lymph nodes may also be
involved in granulomatous changes (such as tuberculo-
sis, sarcoidosis, etc.), fungal diseases, parasitoses (toxo-
plasmosis, leishmaniasis), etc. All these localizations may
also be involved in storage diseases in children, meta-
static lesions of epithelial and non-epithelial tumors, or
at the onset of primary malignant lymph node diseases,
i.e. malignant lymphomas (Hodgkin’s and non-Hodg-
kin’s). In particular, FNA is indicated in case of solid,
painless nodes that occur in clusters, do not decrease
with therapy, or are found supraclavicularly, in the me-
diastinum or intra-abdominally. Recently, useful data in
the differential diagnosis of enlarged lymph nodes have
been provided by ultrasonography (US) diagnosis. The
US characteristics of enlarged lymph node can prove use-
ful for node selection for FNA, and US guidance is irre-
placeable in FNA of deep non-palpable nodes at any lo-
calization (e.g., neck, groin, axilla, abdomen).
In order to issue reports that will be comprehensable,
clear and useful for both the patients and primary care
physicians, the cytologist has to be familiar with clinical
manifestations of the diseases, and to have all relevant
clinical data on the patient available. The best results are
obtained when cytologist performs FNA by himself13.
The procedure also requires close collaboration of the cy-
tologist, the patient and the primary care physician. Col-
laboration with other diagnostic professions, e.g., pathol-
ogy, laboratory, molecular and cytogenetic diagnosis, is
no less important. In such an environment, cytology can
provide optimal results, within the shortest time and at
lowest cost possible. Cytologic report of lymph node FNA
includes description of the cytologic picture, conclusive
opinion in case of definitive finding, and recommenda-
tions for additional diagnostic work-up when the nature
or cause of the disease could not be identified on the cyto-
logic grounds alone, in spite of all additional technologies
applied14.
There are virtually no contraindications for lymph
node FNA, and all lymph nodes are accessible for FNA.
Besides superficial, palpable lymph nodes, FNA can also
be performed in deep seated lymph nodes (abdominal or
mediastinal) with the help of US, computerized tomogra-
phy (CT), magnetic resonance (MR), or endoscopic in-
struments. Superficial lymph node FNA is performed as
an outpatient procedure, without anesthesia, by means
of thin needles (0.5–0.7 mm in diameter, 25 or 22 gauge),
and the patient can resume his/her regular daily activi-
ties immediately upon the procedure. There are no spe-
cial instructions for the patient prior to the procedure,
which causes only minor painful sensation. With due
caution, FNA can also be performed in patients with de-
creased platelet count, minor coagulogram aberrations,
and even those on anticoagulant therapy. Complications
such as hemorrhage at the puncture site or infections are
very rare. Antiseptic measures taken before and after
FNA and appropriate compression at the puncture site
can generally prevent any undesired events. Intra-ab-
dominal and intrathoracic node FNA for diagnostic pur-
pose requires one-day hospitalization (intrathoracic and
retroperitoneal nodes in particular). In case of enlarged
mesentherial nodes or nodes located more superficially
in the abdomen, FNA can be performed in day hospital
where the patient stays for several hours for observation.
These FNA procedures are done under US, CT or MR
guidance, mostly also without local or general anesthe-
sia, with the use of longer and very thin, CHIBA needles
(0.7 mm in diameter, 22 gauge).
Lymphatic tissue is very limited in its ability for mor-
phological reaction to various living agents and their
products (toxins), or chemical substances or other agents
that most commonly cause benign lymphadenopathies.
That means that a number of ethiologic entities will re-
sult in a limited number of types of inflammatory reac-
tion or hyperplasia in affected lymph node15. Various
adjuvant laboratory techniques can help when the mor-
phology alone is not sufficient in achieving an accurate
diagnosis, in lymphomas in particular. The primary role
of cytology is in the diagnosis of reactive hyperplasias, in-
fections, granulomatous and metastatic processes16.
Reactive and inflammatory lesions (nonspecific and
specific) have a characteristic cytologic picture and can
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be quite easily differentiated in the majority of cases,
along with morphology and history data. Malignant lym-
phomas are a heterogeneous group of monoclonal neo-
plastic diseases that originate from the immune system.
Various types of non-Hodgkin’s lymphoma may have
similar morphology with great variations in the origin,
immunophenotype and other biological characteristics.
The most widely used adjuvant technologies in the di-
agnosis of lymphoma include flow cytometry, immuno-
cytochemistry, polymerase chain reaction (PCR), conven-
tional cytogenetics and/or fluorescent in situ hybridiza-
tion (FISH), and kinetic methods (DNA cytometry). FNA
sample can be used in for all these analyses and, depend-
ing on the clinical picture, can be obtained on initial FNA
or later, after in the first cytological report the suspicion
of lymphoma was raised. Immunocytochemistry plays a
major role in the diagnosis and subtyping of malignant
lymphomas, and also in the differential diagnosis of lym-
phomas versus poorly differentiated tumors of another
cell origin. In the latter, there are a number of cellular
antigenes, and using the combinations of various anti-
bodies, in most cases it can be determined whether it is a
lymphoma or a non-lymphoid neoplasm of epithelial,
neuroendocrine, histiocytic, smooth muscle, striated mus-
cle, embryonal, etc. origin; even, in some cases the organ
of tumor origin can be determined16. Flow cytometry
helps in differentiating reactive hyperplasias and malig-
nant lymphomas by determining the lymphatic cell clo-
nality (light kappa/lambda chain restriction) and in lym-
phoma subtyping by determining the degree of lymphatic
cell differentiation17. Very useful is information on rear-
rangement of the immunoglobulin heavy or light chain
gene or T lymphocyte receptor gene, suggesting the lym-
phatic cell B or T clonality, i.e. the diagnosis of malignant
lymphoma. It is determined by molecular diagnosis using
polymerase chain reaction (PCR). Chromosomal aberra-
tions can be identified by conventional cytogenetics or
FISH, that are highly relevant in the diagnosis, subclas-
sification and prognostic assessment of lymphoma. When
lymphoma is cytologically verified on initial testing, it
should be followed by lymph node biopsy and histo-
pathologic analysis. In case of relapse, determination of
disease dissemination and detection of minimal residual
disease, cytologic sample supplemented with adjuvant
technologies is adequate to make the diagnosis12.
The algorithms for the diagnosis of enlarged lymph
node include FNA as the first diagnostic method, fol-
lowed by the adjuvant technologies described above (Fig-
ure 1)13. It should be noted that FNA is associated with
lower risk than operative procedure, especially in immu-
nocompromised patients (e.g., HIV positive), while the
risk of infection for medical staff performing the proce-
dure is also reduced18. Unfortunately, patients with be-
nign lymphadenopathy continue to be quite frequently
referred for surgical extirpation and histopathologic di-
agnosis as the first differential diagnostic option14.
Besides blood cell count (red and white blood cells and
platelet), a hematologic patient’s condition is monitored
by morphological analysis of blood smear, i.e. differential
blood count. In addition to quantitative parameters (ap-
proximate assessment of white blood cell count and
platelet count), differential blood count is irreplaceable
in qualitative analysis of all three blood cell types, i.e. in
the assessment of diseases of red cell line (variation in
the size, shape, chromasia, red blood cell inclusions, etc.),
white cell line (neutrophilic, eosinophilic or basophilic
granulocytes, lymphocytes, monocytes, and other cells
that are not normally found in peripheral blood, a find-
ing of immature forms), and platelet cell line (macro-
platelets, platelet aggregates), which can help in reach-
ing an accurate diagnosis earlier or redirect additional
differential diagnosis. Special attention should be paid to
pancytopenia (a condition characterized by the presence
of anemia, leukopenia and thrombocytopenia), where
bone marrow aspiration is absolutely indicated.
The next step in the diagnosis of hematologic condi-
tions and diseases is bone marrow analysis. FNA is per-
formed in the region of the sternum, spina cristae ante-
rior or posterior, and in small children in the tibial area.
When performed by an experienced professional, the pro-
cedure is very simple, easily done in outpatient setting,
and the patient can immediately resume his/her daily ac-
tivities. Upon disinfection of the puncture site, anesthe-
sia is induced with 2% Xylocaine solution, which acts
promptly and puncture can be performed immediately
upon injecting the anesthetic. The patient should be
warned of the possible allergic reaction and, if there are
data on previous reaction to the anesthetic, bone marrow
aspiration should be performed without anesthesia. Ex-
perience has suggested that the procedure performed in
the region of pelvic bone is less painful and more com-
fortable for the patient. It is essential to have data on the
possible irradiation in the regions where bone marrow is
usually aspirated. Blood cells generally do not recover or
show only poor recovery in the irradiated area so there is
a possibility of getting inadequate marrow specimen. The
very act of marrow aspiration is painful but it only takes
a moment. The site of puncture is sterile covered, and the
patient can remove sterile gauze in 12–24 hours, followed
by normal hygiene of the site. Complications are ex-
tremely rare. Like in other punctures, hemorrhage at the
puncture site may occur in case of inappropriate com-
pression for several minutes required to stop bleeding, or
in case of hemorrhagic disorder. Another complication is
the site infection due to nonsterile manipulation or pre-
mature removal of sterile cover. Very rare complications
are fractures (sternum in particular) in case of extensive
osteolytic lesions due to metastatic bone lesions or multi-
ple myeloma (plasmacytoma). Therefore, the person per-
forming FNA should be familiar with the indication and
should have all history data available. In addition to skil-
ful morphological recognition of normal and pathologic
blood cells and their precursors, the analysis also re-
quires synthesis of other laboratory and clinical data, so
that the report does not only give description that will
not be useful to the primary care physician or clinician.
When the patient is referred for bone marrow FNA, it is
very useful to produce his/her basic hematologic and lab-
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oratory findings, while the cytologist will briefly examine
the patient prior to the procedure to see whether there
are enlarged lymph nodes, spleen enlargement, petechiae
or hematomas on the skin, etc. Upon quantitative (mye-
logram) and qualitative analysis of cells in bone marrow
aspirates, the cytologist gives conclusive opinion, inte-
grating his/her finding in other clinical and laboratory
findings, thus making the analysis meaningful, compre-
hensible and useful to the clinician. If the cytologist con-
siders adjuvant technologies (immunophenotyping, cyto-
genetics, molecular diagnosis, bone biopsy) necessary for
complete evaluation of the disease, he/she can consult
with the primary care physician or hematologist/oncolo-
gist in advance, to arrange for all examinations to be per-
formed in a single act thus avoiding repeating the pro-
cedure15.
Thyroid Cytology
Thyroid gland was the first endocrine gland accessible
to fine needle aspiration and cytologic analysis that was
performed on the palpable thyroid enlargement, nodular
or diffuse. Ultrasound (US) diagnostics enabled con-
trolled – targeted FNA of the nonpalpable lesions.
The introduction of US into the algorithm for thyroid
diagnostics has provoked several questions. The former
incidence of 4–5% palpable thyroid enlargements in the
adult population, suddenly increased: nodular lesions are
found in 40–50% thyroid glands examined by US. The
questions are now: does any thyroid nodule seen on the
US examination mean it is an ill thyroid gland19? Should
we perform FNA on any thyroid nodule seen by US? If
not – how to choose? Then, who is competent to indicate
the FNA of a nonpalpable node? And, finally, who should
perform US-guided FNA of thyroid gland?
In the actual algorithm of the thyroid diagnostics the
palpation and serum TSH estimation are followed by the
US examination, performed by specially trained doctors
– sometimes even cytologists with relevant additional
training in US diagnostics. The same person then indi-
cates the FNA which is performed under the US control
by a cytologist or specially trained doctor (with mini-
mally 100 FNA of the thyroid performed yearly). Then
the cytologist analyses the smears of the aspirated mate-
rial (also with at least 100 thyroid aspirations examined
yearly). It should be emphasised that palpable nodes
should also be aspirated under the US control because of
the possibility of cystic degeneration (the bigger the
node, the more frequent cystic degeneration), where as-
pirated material often has few cellular elements. The fact
that the most frequent thyroid cancer, papillary, has cys-
tic variant in 10–15% of cases, must also be taken into
consideration20,21. Besides the indications for FNA of the
thyroid, there are also some contraindications. One of
them is anticoagulant therapy, because of many blood
vesels in the thyroid. If the aspiration is indicated, an ab-
stinence of minimum three days is necessary from such
therapy. The cytologist has to be informed about all ther-
apeutic measures applied, since the morphology of the
thyreocytes can be changed by hormonal or thyreostatic
therapy.
US-guided FNA of the thyroid and cytological analy-
sis are simple, low-cost and rapid diagnostic methods and
usually give the final diagnosis. The aspirated material is
smeared on the slides, air-dried and stained according to
the May Gruenwald-Giemsa method. The cytological re-
port can be issued on the same day. The cytologist can in-
dicate various additional analyses if necessary (cyto-
chemistry, immunocytochemistry, PCR, thyreoglobulin
or calcitonin level determination in the aspirate).
The cytological report should contain the description
of the smears and the conclusion – the diagnosis if possi-
ble, or suggestions for additional procedures, if neces-
sary. The aspirated material can be adequate or inade-
quate for cytoanalysis. The inadequate material may be
obtained because of insufficient education or experience
of the cytologist or the US specialist, but also because of
to much blood in the aspirate, when there are not enough
cellular elements in the smears, or smears cannot be
made if the blood coagulates on the slide. Inadequate
samples should not exceed 15% of all thyroid aspirations.
The cytologist indicates repeating of FNA in such case.
The adequate material can be classified into three main
groups: benign lesions (50–90%), malignant lesions (1–
10%) and suspect lesions (5–20%). The benign lesions
can be diffuse (hyperthyreosis – Graves disease, hypo-
thyreosis – struma lymphomatosa), or, more frequently,
nodular. The inflammatory thyroid diseases can be dif-
fuse or focal. The thyroid nodes are most often coloid
cysts and they can be diagnosed by the US without cyto-
logical verification. The nodular cystic degeneration or
hyperplastic nodes should be diagnosed cytologically, and
the epithelial atypia is an indication for the control. Cy-
tologically diagnosed inflammatory lesions should be ultra-
sonographically controlled 1–2 times yearly. Subacute
thyroiditis should be controlled by the US 3–4 months af-
ter the diagnosis, since the thyroid should be completely
restored during this period. The US control is recom-
mended after a period of six months in all other benign
lesions.
Malignant lesions of the thyroid gland are present in
1–10% of all thyroid diseases, depending on statistical
method (investigation of thyroid nodes or of the total
gland). The number of newly detected thyroid cancers
has increased threefold in the last 35 years, owing (at
least partially) to new methods of detection (US, FNA).
Papillary cancer is the most frequent one (80–90%) and it
is usually easily recognized in FNA smears. The cytolo-
gist indicates the US examination of the neck lymph
nodes and FNA if needed, as well as the surgical therapy.
There are no solid cytologic criteria for differentiating
malignant from benign follicular tumors of the thyroid.
The preoperative diagnostics – cytomorphology, cytoche-
mistry, immunocytochemistry, PCR and genetics cannot
differentiate an adenoma and a follicular carcinoma.
Pathohistological finding of capsular or vascular pene-
tration of tumor is the only evidence of malignancy. Some
hormonal analyses (thyreoglobulin estimation in aspi-
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rate or serum) and scintigraphy of the thyroid can distin-
guish a hormonally active tumor (adenoma) from a hor-
monally inactive tumor and nodular hyperplasia. The
endocrinologist can decide a follow-up or surgical treat-
ment on the basis of the US finding (size or dynamics of
the node enlargement), scintigraphy findings, age, func-
tion of the thyroid22,23. Oncocytic tumors, according to
the WHO, represent a subtype of follicular tumor, but
they are cytologically quite different from other tumo-
rs24. The percentage of follicular cancers has declined af-
ter the introduction of iodine addition to the salt and this
has caused relative increase of pappilary tumors. The
same is the case with anaplastic thyroid cancers25. The
third thyroid cancer by prevalence is medullary carci-
noma (5–10%). This tumor is of genetic origin in nature,
caused by a mutation in the RET proto-oncogene in
25–30% of cases25,26. This form is classified as familial
medullary carcinoma or as a part of the multiple endo-
crine neoplasia type 2 (MEN2). Preoperativelly, cytologi-
cal analysis and estimation of calcitonin level are the di-
agnostic methods for this type of tumor. According to the
WHO, there are twelve histological variants of medullary
carcinoma24. In 30–40% of the cases, metastases in neck
lymph nodes are found by the US examination. Such ex-
amination is very important, since there is no other ther-
apeutic measure except surgical removing of both the
primary tumor and the metastatic lymph nodes. It should
be mentioned here that all family members have to be ge-
netically examined and, if the pathological gene is found,
total thyreoidectomy is indicated, especially in children
under five years of age.
Mixed, follicular-medullary, poorly differentiated thy-
roid cancer and other rare types of thyroid malignancies
are now surgically treated. The finding of p53 gene muta-
tion is characteristic for anaplastic thyroid cancer (90%)27.
The primary thyroid lymphoma is present with 2–4% of
thyroid malignancies. The women: men ratio is 5:1 and
lymphomatous struma is often the underlying condition.
They appear in older age (after 60 years). It is important
to recognize them cytologically since surgical excision is
not an adequate treatment28.
Metastatic tumors in the thyroid gland are rare. In
those rare cases, the rule of cytology is in the evaluation
of the tumor extension (or in searching for an unknown
primary tumor), as well as in the choice of the treatment.
Most frequently, metastases are from kidney, breast,
lung, gastroinestinal organs and from melanoma29.
In children, thyroid disorders should be evaluated by
the TSH estimation, US examination – especially for de-
tection of congenital aberrations as ectopic thyroid gland,
dysgenesis of a lobe or thyreoglossal duct cyst. Scin-
tigraphy is not recommended in children. Thyroid tu-
mors in childhood are very rare (1–2/1,000.000) and they
usually present as palpable nodes or enlargement of the
thyroid, often with metastases (neck lymph nodes 50–90%,
distant metastases 15–30%). But, their prognosis is be-
tter than in adults, regardless of the extension of the tu-
mor. They are papillary cancers in more then 90% of
cases. Thyroid cancers which can be related to Chernobil
accident are more aggressive and have gene mutation
RET-PTC 330. They are cytologically most often diffuse
and sclerosing. In the relevant articles the incidence of
thyroid cancer in children from the Chernobil area is de-
scribed to be up to 20 times higher than in general popu-
lation.
Papillary cancer can also be found in the cyst of the
ductus thyreoglossus and the surgical removing of such
cyst is therefore recommended31.
As known, tumors of the thyroid are more frequent in
women and differentiate cancers are frequent in the gen-
erative age, so they can appear in the pregnancy. Diag-
nostic methods are palpation, US examination and FNA
if necessary. Surgical treatment is recommended in the
second trimester of the pregnancy. Scintigraphy is not
permitted during the whole pregnancy period as well as
in the period of nursing32,33.
Finally, the role of cytology and the responsibility of
the cytologist should be emphasized since every cytologi-
cally diagnosed thyroid cancer, regardless of its dimen-
sions, should be removed by total thyreoidectomy. It is
clear that the communication between primary practitio-
ners and cytologists is very important and it can and
should be improved.
Pulmonary Cytology
Most patients with lesions suitable for specific pulmo-
nary cytological analysis in primary care are symptom-
atic ones. Predominant indication for cytological analysis
is productive cough with or without blood traces in
sputum34. Abnormal radiological finding in asymptom-
atic patient is also indication for further diagnostic pro-
cedures as bronchoscopy that can be performed in outpa-
tients, or other invasive procedures. Asthma and allergic
reactions with productive cough are suitable for sputum
examination, therefore finding of eosinophilic granulo-
cytes is important for further treatment. Screening for
asympthomatic patients with lung cancer was promising,
but results are controversial35,36. Sputum immunocyto-
logy promises much greater sensitivity than conventional
sputum cytology. There are a series of both genetic and
molecular alterations found in lung cancers and prene-
oplastic lesions. The presence of these genetic and molec-
ular changes in sputum may be clinically useful in identi-
fying patients with cancer or those at high-risk of develop-
ing cancer. Identified changes in lung cancer include the
detection of loss of heterozygosity (LOH), microsatellite
alterations or instability (MIN), mutations in specific
genes, cancer specific methylation changes and the detec-
tion of mutant gene products. This suggests that chromo-
somal analysis may allow detection of premalignant
changes in the airway epithelium long before it would be
apparent on CT and may serve as a high-risk marker for
lung cancer37.
Some studies include sputum cytological and molecular
biomarkers analysis in subjects at high-risk for lung can-
cer (30 pack-years smoking history and chronic obstruc-
tive pulmonary disease defined by spirometry). Prelimi-
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nary results showed that severe atypia or worse cytological
changes in the sputum represent a high-risk for develop-
ing lung cancer within a short time36. Specimens in pul-
monary cytology can be exfoliative and FNA-s. Among
exfoliative most common are spontaneously obtained
sputum, rarely induced sputum, smears of nasal mucosa,
aspirates, bronchoalveolar lavage fluid (BALF), brush
imprints and biopsy imprints (lesions in bronchus or
lungs) obtained during bronchoscopy, pleural effusions
and imprints of pleural needle biopsies, intraoperatively
obtained imprints of lung, pleural and mediastinal tu-
mours, lesions and lymph nodes38. Instructions for spu-
tum sampling are necessary for adequate cytological
analysis. FNA-s can be obtained during bronchoscopy: le-
sions in bronchus, transtracheal, transbronchial punc-
ture of lymph nodes, substrates and tumours in lungs
and mediastinum in local and general anaesthesia38,39. Of
great diagnostic value is radiologicaly guided (ultrasound,
x-ray or CT) percutaneous transthoracic FNA. Subcuta-
neous and cutaneous lesions and peripheral lymph nodes
are suitable for FNA-s and cytological analysis. All cyto-
logical reports have to be properly described with conclu-
sion made by clinical cytologist wherever possible. Malig-
nant cytological reports are usually made according to
working WHO classification of lung neoplasm’s and ser-
ve as clear directions for further procedures40. Cytologi-
cal classification in small and non-small cell lung cancer
is still in use, but is inadequate. New strategies in cancer
treatment require differentiation between squamous cell
carcinoma and adenocarcinoma. More complex are non-
specific cytological reports with mild epithelial abnor-
malities, goblet or basal cells hyperplasia’s, regular or
atypical squamous metaplasia. Interpretation of these
reports requires knowledge of other clinical data known
to general practitioner or other specialist38,39. Presence
of inflammatory cells with fungi or bacteria is usually
conclusive for specific cytological diagnosis. Reports with
atypical squamous metaplasia and granulomatous le-
sions with or without necrosis require verification with
repeated or different diagnostic procedures.
Gastrointestinal Cytology
Cytodiagnosis has an important place in routine eval-
uation of gastrointestinal organs, and has been dramati-
cally improved by development of endoscopic techniques.
The primary care physician does not have direct influ-
ence on the decision whether such a cytologic evaluation
will be performed, but must be aware of the option. The
cytologic analysis is made upon gastroenterologist’s re-
quest, in the course of patient evaluation or during endo-
scopic examinations. These examinations are expensive
and unpleasant for the patient. It must be kept in mind
that tissue biopsies and cytologic specimens are diagnos-
tically complementary and their combination improves
the overall diagnostic accuracy. Currently, cytology is
underused in the gastroenterology workup. An aim of cy-
tology in everyday gastroenterology practice is early de-
tection of malignancy, but some inflammatory conditions
can also be discerned. Except for primary diseases of gas-
trointestinal organs, it has become possible to diagnose
malignant processes in neighbouring organs like lungs,
lymph nodes, spleen, kidney, adrenal gland and retro-
peritoneal region. The metastatic disease can be readily
diagnosed too, often in the liver, the lymph nodes or in
the peritoneal space. Distinguishing a primary malig-
nant process from a secondary one is necessary because
the metastases may be the first sign of disease. In this
case, the cytologic analysis can render a definitive diag-
nosis or indicate the need for other diagnostic proce-
dures. Other clinical findings are of great value to a cytol-
ogist and have a great influence on the final cytologic
report41,42.
The material for cytologic analysis can be obtained by
brushing during endoscopic interventions, e.g. oesopha-
gogastroduodenoscopy, colonoscopy or retrograde chol-
angiopancreatography. The flexible fiberoptic endoscope
permits visually directed brushings of any grossly evi-
dent mucosal abnormality. During these procedures, a
small, circular brush is pushed through the endoscope
and moved over the suspected lesion. An advantage of
this technique is that it permits sampling of a larger area
than by biopsy forceps. It is important in cases of dys-
plastic changes and early carcinomas when the appear-
ance of mucosa is still normal. Another advantage is that
the brush is more flexible and allows evaluation of ste-
notic lesions. It should be noted that collecting material
for cytology should be performed before biopsy in order
to avoid contamination by blood and debris. Exfoliative
cytology is the method used for superficial lesions41,43.
Transmucosal fine-needle aspiration (FNA) cytology has
its greatest advantage in diagnosing submucosal neo-
plasms (carcinoids, gastrointestinal stromal tumors and
lymphomas), stenosing tumors, highly infiltrative and
necrotic lesions. An ultrasound (US), or other imaging
technique guided percutaneous FNA cytology is often
performed not only on liver, but on deeply seated retro-
peritoneal lesions and other abdominal organs as well.
Ascites is sampled in the same way41,44. Endoscopic ultra-
sound guided fine-needle aspiration (EUS FNA) is a rela-
tively new technique which improves visualization of the
gastrointestinal wall, abdominal organs (pancreas, liver,
left kidney, spleen, adrenal glands), and periluminal lymph
nodes (intrathoracic and intra-abdominal)45,46. These en-
doscopes possess specific channels through which the ul-
trasound device and cytologic needle, may be inserted. It
is used most frequently to diagnose early pancreatic tu-
mors but virtually all solid or cystic structures in the
scope of the instrument can be sampled. It is possible to
sample more than one site during the same procedure.
The brushes or aspirated material is placed on glass
slides, then air-dried or imersed in 95% alcohol. It is pos-
sible to obtain additional material for cytospin and flow
cytometry if the brush or needle is rinsed in saline. The
accuracy of EUS-FNA is enhanced with the cytopatolo-
gist presence during the procedure, with immediate mac-
roscopic examination of yielded material and, in some
cases, rapid microscopic evaluation for material ade-
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quacy. The ability to obtain cytologic material under di-
rect visualisation provides an opportunity for prompt
and accurate diagnosis. The cytologic examination pro-
vides information to guide disease-specific therapeutic
interventions and prevent unnecessary operative proce-
dures. An effective collaboration between the cytopa-
thologist and endoscopist is necessary. The probability of
yielding satisfactory material for cytologic analysis de-
pends on the gastroenterologist’s experience, nature of
sampled lesion, and presence of cytotehnologist who pre-
pares smears on site, but also depends on the brush or
needle type. The cytologist’s experience and access to rel-
evant clinical data is another important issue. A cytolo-
gist must be aware of morphology of normal tissue or ar-
tifacts that can be found in specimens from the gastroin-
testinal tract. The same cytomorphologic picture may
have varying importance in different clinical conditions.
The decision about repeating the procedure is based on
cellularity and adequacy of the yielded material and on
fitting the finding into particular clinical circumstances.
The neoplastic cells may have various levels of differenti-
ation with respect to morphological and functional re-
semblance to normal cells. When they are well-differenti-
ated there may be some difficulties to recognize their
neoplastic nature. A similar problem is when they are
poorly differentiated and the trouble is to reveal their or-
igin. The cytologic diagnosis is based on a variety of
cytomorphologic characteristics like nuclear and cyto-
plasmic appearance, presence of nucleoli, chromatin stru-
cture, cohesion between the cells, way of cell’s clustering,
presence of extracellular material etc. That counts for
any cytologic specimen, and any organ. The ancillary di-
agnostic tests like immunocytochemistry and flow cy-
tometry make a usefull contribution in these situations.
These techniques, including molecular testing, have both
a prognostic and a diagnostic value. The cytologic report
may be final or indefinite, which would indicate necessity
to repeat the examination.
Although there is no direct information exchange be-
tween the cytologist and primary care physician because
communication towards the primary care is done by the
gastroenterologist, this is no reason for the primary phy-
sician to hesitate to contact the cytologist in order to
clarify the dilemmas and seek out new information about
his patient.
Breast Cytology
Breast cancer is the most common malignant disease
in women and its early detection is vital for women, of-
fering timely treatment and in many cases complete
cure. Approximately 50% of patients develop metastatic
disease, which is usually a terminal state. The symptoms
of breast cancer are changes in the shape and size of the
breast, enlarged node in the breast or axillary region,
nipple retraction, changes in the appearance of the skin
of the breast or nipple (thickening, redness, inflamma-
tion) and nipple discharge bloody or clear fluid that
arises from the nipple). These warning signs can be
found by breast self-examination, which is necessary to
perform on a regular basis, e.g. monthly, at the same
time (5th to 8th day of the menstrual cycle, counting from
the first appearance of menstruation). If the woman does
not have menstrual cycle anymore, breast self-examina-
tion should continue on the same day each month. How-
ever, any breast nodule does not necessarily mean a ma-
lignant tumor, but it is important that the woman sees
the doctor immediately to identify the origin of the lump.
The risk of breast cancer increases with age. Attention
should be paid to history data such as breast cancer in
the family (mother, grandmother or sister, age of family
members at disease onset), older primigravida (delivery
of the first child after age 30), time of exposure to
estrogens, etc. The women that carry inherited muta-
tions in the BRCA1 or BRCA2 gene have a lifetime risk of
breast cancer of more than 80 percent; this also applies
to the women with diagnosed malignant changes of
breast (especially if the lesions were bilateral) as well as
those with previously diagnosed atypical lesions (atypical
ductal or lobular hyperplasia), and with lobular or ductal
carcinoma in situ.
What is the place of cytology in the diagnosis of breast
disease? Algorithms for early detection of breast cancer
cannot prevent the disease, but can help identify cancer
in the earliest stages when treatment is most successful.
Primary care physician is the first professional to iden-
tify the risk group of women according to the above listed
parameters and to inform them how to do breast self-ex-
amination in addition to clinical examination (inspection
and palpation). Ultrasonography (US) as a diagnostic
method in early detection of breast cancer is the method
of choice for younger women (age 40). Mammography is
an irreplaceable imaging diagnostic method in detecting
malignant breast disease, especially in the early stages. It
is performed in premenopausal women in the first half of
the cycle, significantly increasing the accuracy of US di-
agnosis of malignant and benign breast disease. In wo-
men younger than 40, mammography is only performed
if needed47. In recent years, there have been even more
requests for magnetic resonance imaging (MRI). It is pre-
ferred for being a noninvasive diagnostic method and
women are not exposed to radiation. However, MRI dis-
advantage lies in the fact that it significantly raises the
cost of diagnostic work-up and is unavailable for most pa-
tients. The question remains whether it can fully replace
tissue diagnosis (cytology or histopathology). Fine needle
aspiration cytology (FNAC) has been used in the diagno-
sis of breast lesions for years and remains a cost-effective
option for diagnosing breast changes. FNAC has a unique
role in three main areas: (a) diagnosis of symptomatic pa-
tients as part of triple assessment; (b) staging of breast
cancer, especially preoperative aspiration of axillary
lymph nodes and/or intraoperative imprint cytology of
sentinel lymph nodes; and (c) screening for distant
metastases48. Indications for FNA and other tissue diag-
nostic tests are: clinically suspicious (palpable) breast le-
sions, enlarged regional lymph nodes, skin changes, if
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necessary bone marrow aspiration, US or mammogra-
phic suspicious (impalpable) lesions of the breast and re-
gional lymph nodes, discharge (either spontaneous or
provoked); breast nipple changes, and intraoperative cy-
tology (imprint).
What conditions are required for successful breast
FNA? Guidance for FNA is usually provided under ste-
reotactic-, US- and more recently MRI guidance. FNA re-
quires team work. As noted, cytologists training is cru-
cial, but educating referring clinicians and patients about
the benefits and potential pitfalls of FNA is as impor-
tant49,50. The accuracy of cytological diagnosis of cancer
depends on team work51, visualization of the lesion dur-
ing the FNA (US or stereotaxis), experience of the staff
performing FNA, and adequacy of the sample obtained,
proper smear preparation and processing and, finally, the
experience of the cytologist in interpreting the breast
samples47. FNA may be performed by a cytologist, clini-
cian, or radiologist. It has been repeatedly demonstrated
that the best FNA result is obtained if the person inter-
preting the smears is the same person that performed
the FNA. In women of childbearing age, samples for cyto-
logic analysis of palpable and impalpable lesions are ob-
tained by use of a fine needle (diameter 0.8 to 0.9 mm in
diameter and 18–20 gauge) in the first half of the men-
strual cycle (usually day 5–8 of the cycle), and further
procedure depends on the cytologic, US and/or mammog-
raphy findings. If the cytology finding is negative, and
the mammography and US findings are suspicious, then
the patient is referred for histopathologic verification.
Discharge is also obtained in premenopausal women in
the first half of the cycle (three independent samples in
three days); further procedure depends on the cytology
finding. Core biopsy as an alternative diagnostic method
should be used when it is likely to provide valuable
diagnostic information, e.g. in the presence of microcalci-
fications and overt clinical malignancies scheduled for
preoperative chemotherapy48.
According to the recommendations issued by the Cro-
atian Society of Clinical Cytology Task Force, the breast
FNAC report includes: material adequacy, microscopic
description, and cytological opinion. Cytological opinion
includes definitive diagnosis if possible: cysts, inflamma-
tory lesions, fibroadenoma, fibrocystic disease with or
without proliferative epithelial changes (with or without
atypical hyperplasia), or malignant lesions. If it is not
possible to make definitive diagnosis on FNA sample, we
follow mandatory recommendations for further manage-
ment: (A) repeat FNAC if diagnosis is: [1) atypical hyper-
plasia, probably benign; and 2) atypical hyperplasia and
hormone replacement therapy (HRT) – repeat FNAC af-
ter 3-month pause in taking HRT]; (B) core biopsy if di-
agnosis is: [1) repeat FNAC with atypical hyperplasia; 2)
FNAC negative, but US – and/or mammography-suspect
lesions; 3) cytologically undefined, suspect lesions; and 4)
microcalcifications if stereotactic aspiration biopsy is ne-
gative]; or C) open surgical biopsy [1) CB-suspect lesions
or 2) FNAC/CB – malignant lesions]52 (Figure 2).
Urologic Cytology
Family physicians must be informed about the possi-
bilities of cytologic analysis in their everyday work. It is
an inexpensive and noninvasive method for the evalua-
tion of the most common patients’ complaints and abnor-
mal results of routine urine analysis. It is useful in the
detection and monitoring of both renal and urinary tract
disorders. The scope of clinical cytology in urology is
wider than cytological analysis of urine, but limited to
urologist’s decision. This is particularly true when it co-
mes to the diagnosis of prostate diseases, evaluation of
renal masses or in clinical staging of malignant neo-
plasms. The common prostate diseases, benign hyperpla-
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Fig. 1. Algorithm for the diagnosis of lymphadenopathy. FISH –
fluorescence in situ hybridisation, FNAC – fine needle aspiration
cytology, PCR – polymerase chain reaction, PSA – prostate spe-
cific antigen, Tg – thyreoglobulin [KOCJANG, 58 (2005) 561.].
US-guided FNAC of BL
malignant benign suspicious benign malignant
malignant
open surgical biopsy
(PHD)
open surgical biopsy
(PHD)
suspicious
follow up
open surgical biopsy
(PHD)
benign
Stereotactic FNAC of BL
with/without MC
Core needle biopsy
Fig. 2. Algorithm for the tissue diagnosis of breast lesions (ac-
cording to the recommendations issued by the Croatian Society of
Clinical Cytology). BL – breast lesions, US – ultrasound, FNAC –
fine needle aspiration cytology, MC – microcalcifications, PHD –
pathohistological diagnosis.
sia and carcinoma are very frequent in older male popu-
lation and are generally present with obstructive sim-
ptoms and/or elevated serum prostate specific antigen
(PSA). In the last two decades there is a trend to diag-
nose them only by core-needle biopsy. The fine-needle as-
piration of prostate is underestimated and underused de-
spite its advantages like fast, accurate diagnosis, minimal
discomfort for patients, lower costs and lower frequency
of complications. Bladder cancer, one of the most com-
mon malignancy in adults commonly presents with pain-
less hematuria, but sometimes may cause cystitis-like
symptoms. Obstructive symptoms are characteristic for
tumours of the renal pelvis, ureter and urethra. Trans-
itiocellular carcinomas, the most common type of uri-
nary tract tumors, may evolve at any point of urothelial
lining, including bladder, ureters, urethra and renal pe-
lves. These carcinomas may arise simultaneously at vari-
ous points along the urinary tract, frequently recur and
show heterogeneous ability to invade and metastasize.
Early detection prevent tumor invasion into the tissue,
therefore improving the patient’s prognosis. In both acute
and chronic infections cytologic urine analysis demon-
strates many leukocytes and characteristic cell changes,
and the infectious agent may also be identified (bacteria,
yeasts, parasites or cytopathogenic effect on cells caused
by viruses). It has the possibility to indicate kidney dis-
ease by the finding of renal tubular cells, casts and mor-
phologically changed erythrocytes53–55.
The volume of urine samples to be collected into a
clean container should be about 50ml. Three consecutive
samples of urine appear to be optimal for the cytologic
evaluation. The urine specimens can be spontaneously
voided or obtained instrumentally by catheterization.
Washings and brushings are other methods for collecting
abundant, well-preserved specimens from the urinary
tract and can be performed during cystoscopy, but these
procedures are invasive and expensive and carry the risk
of infection. Selective catetherization of the ureters and
renal pelves with irrigation of saline improves cytologic
detection of tumors in these areas and allow determina-
tion of precise origin of abnormal cells – the information
that can not be obtained from voided urine specimen. Al-
though the first spontaneously voided morning urine
may provide a more cellular sample, degenerative chan-
ges are more prominent. The cells in a midday urine
specimen are often better preserved, but fewer cells may
be present. Patients provide their fresh urine samples in
the cytology laboratory after the usual morning hygiene
at home. Lowering the urine pH by the administration of
1 g of vitamin C at bedtime, prior to collection of the
urine, may improve cellular preservation. A midstream,
clean-catch specimen is recommended to avoid vaginal
contamination in female patients. A midstream speci-
men, not necessarily clean catch, is recommended for
male patients. Clinical history is of utmost importance.
This information includes the present symptoms, basic
laboratory findings and any kind of previous urologic
treatment, surgery, chemotherapy or immunotherapy.
Prior history of cancer and any condition that places a
patient in a high risk category for malignant or pre-ma-
lignant disease must be noted.
Cytologic urine analysis has low sensitivity and high
specificity for detecting carcinomas. This means that
there are no or few false positive findings and significant
number of false negative results caused by reasons listed
here. The likehood of correctly diagnosed carcinoma in
urine specimen rises with grade of differentiation and ag-
gressiveness, whether in situ or invasive. Some of these
tumours are small and may not be apparent at cy-
stoscopy or by other diagnostic procedures. Similarly, the
cytologic diagnosis of low grade carcinoma is often diffi-
cult, because these tumours do not shed abundant cells
as the higher grade lesions do. Neoplastic cells can mor-
phologically resemble normal urothelial cells or their
changes may be reminiscent of reactive changes caused
by calculi or instrumentation. The mechanical damage in
these cases may induce cellular atypia and the shedding
of more numerous epithelial cells56. Unsatisfactory sam-
ples due to contamination by squamous cells, degenera-
tive changes and inflammation contribute to this prob-
lem. Finding nonspecific changes on cells, such as atypia
or dyskaryosis require follow-up on the patient. Simi-
larly, cytologic diagnosis of an atypia on the prostate
gland epithelial cells means morphologic changes, differ-
ent from normal cells but not displayed enough to diag-
nose carcinoma. It encompasses both reactive and neo-
plastic changes on cells. In such situations, repeating the
cytology examination after a certain time is the only
choice.
General practitiones should be familiar with options
and limitations of cytology. Ideally, a physician should
know exactly which cytology laboratory is receiving spec-
imens or patients refered by him or her, in order to be
able to clarify possibile dilemmas in direct contact. When
indicated, the cytological report contains a recommenda-
tion on further management of the patient.
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KLINI^KA CITOLOGIJA I PRIMARNA ZDRAVSTVENA ZA[TITA DJECE I ODRASLIH
S A @ E T A K
Klini~ka je citologija medicinska dijagnosti~ka struka, poznata poglavito kao Papa test u ginekologiji, ali se ona
primjenjuje u gotovo svim medicinskim strukama. Njene su prednosti visoki stupanj to~nosti, jednostavna tehnika,
mala ili nikakva agresivnost i mali tro{kovi, ali se unato~ tome ne koristi dovoljno u praksi. U medicinskoj praksi, kao i
u medicinskoj znanosti, a i u edukaciji, danas je na prvom mjestu profit, a ne stvarna dobrobit bolesnika. Lije~nici u
primarnoj zdravstvenoj za{titi nemaju dovoljno prilike da upoznaju sve mogu}nosti citolo{ke dijagnostike, iako bi to
bilo potrebno upravo zbog njene prednosti u smanjenju tro{kova i koristi za bolesnike. O toj temi odr`ana je rasprava za
okruglim stolom na 4. Hrvatskom kongresu klini~ke citologije, odr`anom u Splitu od 11. do 14. listopada 2009. godine u
organizaciji Hrvatskog dru{tva za klini~ku citologiju Hrvatskog lije~ni~kog zbora, usmjerena na informiranje lije~nika
u primarnoj zdravstvenoj za{titi djece i odraslih o mogu}nostima citolo{ke dijagnostike. Bilo je rije~i o indikacijama za
citodijagnostiku u zaraznim bolestima (T. Jeren i A. Vince), hematologiji (I. Kardum-Skelin), pulmologiji (S. Smoj-
ver-Je`ek), bolestima {titnja~e (A. Kne`evi}-Obad) i dojke (I. Kardum-Skelin), te u gastroenterologiji i urologiji (G.
Kai}), kao i o tehni~kim postupcima te o interpretaciji citolo{kih nalaza. Voditeljica rasprave (@. Znidar~i}) odr`ala je
uvodno izlaganje o klini~koj citologiji i njenoj ulozi u primarnoj zdravstvenoj skrbi. U zaklju~ku je nagla{ena potreba
bolje komunikacije izme|u lije~nika primarne zdravstvene skrbi i citologa. U ~lanku su prikazani tekstovi ove rasprave.
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